Clinical trials: Breast Neoplasms, completed
Axillary Dissection
Axillary Reverse Mapping for Breast Carcinomas
Distinct arm from breast axillary dissection (AD), or axillary reverse mapping (ARM), involves retrieving all breast related nodes while leaving intact the main lymphatic drainage chain of the upper limb.
- Trial name
- SENTIBRAS (NCT01146158)
- Testing
- Axillary dissection for breast carcinomas
- Where
- France
- Volunteers
- 210 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HER2-positive Breast Cancer, Recurrent Breast Cancer
Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
This phase I trial studies the safety and the ability to expand laboratory-treated T cells when given together with cyclophosphamide or denileukin diftitox in treating patients with human epidermal growth factor receptor…
- Conditions
- HER2-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT00228358
- Testing
- ex vivo-expanded HER2-specific T cells, cyclophosphamide, denileukin diftitox
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Washington
Breast Cancer
Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)
This is a prospective, open-lable Phase II clinical trial (ORCHID study) evaluating the effectiveness and safety of oral vinorelbine or capecitabine combined with trastuzumab as adjuvant treatment for patients with lymph node…
- Trial name
- ORCHID (NCT04296162)
- Testing
- Vinorelbine, Capecitabine, Trastuzumab
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Fudan University
Breast Cancer, Ductal Carcinoma in Situ
The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery.
The investigators have developed a novel ultrasound-guided nerve block indicated primarily for breast cancer surgery that mimic a thoracic paravertebral block (TPVB) - hitherto the internationally accepted regional anesthesia…
- Trial name
- NCT04248179
- Testing
- Ropivacaine injection, Saline 0.9%, Sufentanil and PONV prophylaxis
- Where
- Denmark
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Zealand University Hospital
Breast Cancer, Radio Dermatitis
Autologous Fat Infiltration Versus General Measures as Treatment in Radiodermatitis Induced for Radiotherapy in Breast Cancer Patients
Radiodermatitis is a major problem in oncologic patients, fat grafts previously used for cosmetic procedures have been shown to have regenerative power due to their stem cell content.
- Conditions
- Breast Cancer, Radio Dermatitis, Radiotherapy
- Trial name
- NCT07023796
- Testing
- Autologous fat filtration
- Where
- Mexico
- Volunteers
- 22 people
- Sponsor
- Instituto Mexicano del Seguro Social
Breast Cancer
Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This randomized phase II trial is studying two different schedules of everolimus to see how well they work in treating…
- Trial name
- NCT00255788
- Testing
- everolimus
- Where
- 5 sites in Canada
- Volunteers
- 49 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer
Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates
The investigators plan to study the efficacy of the combination of weekly paclitaxel + BIBF 1120 in early breast cancer using a neoadjuvant schedule and a randomized phase-II trial design, comparing the efficacy vs.
- Trial name
- NCT01484080
- Testing
- BIBF + Paclitaxel, Paclitaxel
- Where
- 3 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III
Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer
Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing…
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer
- Trial name
- NCT00407888
- Testing
- doxorubicin hydrochloride, cyclophosphamide, filgrastim
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Washington
Breast Cancer
OA for Breast Cancer NAC Response
This is an early research and development study. The objective of this study is to determine the feasibility of the Imagio OA/US Breast Imaging System to detect complete breast cancer pathologic response to neoadjuvant therapy as…
- Trial name
- NCT05337280
- Testing
- Imagio OA/US
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Seno Medical Instruments Inc.
Breast Cancer
Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not
This is a biomedical study of interventional type which includes 29 patients on 9 months: 8 months recruiting and 1 month follow up.
- Trial name
- OXYTAM (NCT01553903)
- Testing
- Tamoxifen,, Exemestane, Anastrozole
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Institut Claudius Regaud
Advanced Breast Cancer
Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
The study is being conducted to evaluate the pharmacokinetics and safety of SHR-A1811 monotherapy and in combination with Ritonavir or Itraconazole in subjects with HER2-expressing advanced breast cancer.
- Trial name
- NCT06710990
- Testing
- SHR-A1811, Ritonavir, Itraconazole
- Where
- 2 sites in China
- Volunteers
- 17 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Breast Neoplasms
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)
The purpose of the study is to evaluate the efficacy of the triplet of ridaforolimus, dalotuzumab and exemestane compared to the combination of ridaforolimus and exemestane in post-menopausal participants with breast cancer.
- Trial name
- NCT01605396
- Testing
- Ridaforolimus, Dalotuzumab, Exemestane
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
Alopecia, Breast Cancer
Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling
Persistent alopecia following adjuvant docetaxel for breast cancer is a side-effect that has been recently described. This pilot trial explores the capacity of a cooling cap (Elasto-gel) to prevent persistent alopecia in breast…
- Trial name
- NCT00515762
- Testing
- elasto-gel cap
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Hospital San Carlos, Madrid
HER2-negative Metastatic Breast Cancer, HER2-positive Circulating Tumor Cells
DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs
The HER2 status in breast cancer patients may change during the course of the disease. In 30% of initially HER2-negative patients with circulating tumor cells (CTC), HER2-positive CTCs can be detected in peripheral blood…
- Trial name
- DETECT III (NCT01619111)
- Testing
- standard chemo- or endocrine therapy, standard chemo- or endocrine therapy + Lapatinib
- Where
- Germany
- Volunteers
- 105 people
- Sponsor
- Prof. Wolfgang Janni
Breast Cancer
Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients
The goal of this observational study is to learn about the effects of metronomic chemotherapy in advanced breast cancer patients.
- Trial name
- NCT06373744
- Testing
- cyclophosphamide , methotrexate , vinorelbine ,capecitabine
- Where
- China
- Volunteers
- 597 people
- Sponsor
- Sun Yat-sen University
Breast Cancer With Low to Intermediate HER2 Expression
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Purpose of this trial: 1. To assess the efficacy and safety of NeuVax™ administered with adjuvant Leukine® (sargramostim, GM-CSF). 2. To evaluate and compare the disease free survival (DFS) in the vaccinated and control subjects.
- Trial name
- PRESENT (NCT01479244)
- Testing
- NeuVax™ vaccine, Leukine® (sargramostim, GM-CSF) and water for injection
- Where
- 197 sites in United States, Bulgaria and 11 more
- Volunteers
- 758 people
- Sponsor
- Galena Biopharma, Inc.
Breast Cancer
Does Scar Massage Improve Postoperative Pain and Function in Women With Breast Cancer?
All patients undergoing breast cancer surgery are left with scars which can significantly affect their physical and psychological well being.
- Trial name
- NCT00175344
- Testing
- Scar massage.
- Where
- Canada
- Volunteers
- 96 people
- Sponsor
- University of British Columbia
Breast Cancer
Combination Chemotherapy in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells following…
- Trial name
- NCT00047099
- Testing
- cyclophosphamide, docetaxel, epirubicin hydrochloride
- Where
- 2 sites in Germany
- Volunteers
- 446 people
- Sponsor
- Ludwig-Maximilians - University of Munich
ER+ and AR+ Breast Cancer
Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer
The purpose of this study is to determine if GTx-024 at different dosages (9 mg or 18 mg) is effective and safe in the treatment of patients with metastatic or locally advanced Estrogen Receptor (ER)+ and Androgen Receptor (AR)+…
- Trial name
- NCT02463032
- Testing
- GTx-024
- Where
- 4 sites in United States
- Volunteers
- 136 people
- Sponsor
- GTx
Metastatic Breast Cancer
A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer
This Phase Ib-IIa, multi-institutional, open-label, dose-escalation study is designed to evaluate the safety, tolerability, pharmacokinetics and feasibility of trastuzumab emtansine (T-DM1) administered by intravenous (IV)…
- Trial name
- NCT00951665
- Testing
- paclitaxel, pertuzumab [Perjeta], trastuzumab emtansine [Kadcyla]
- Where
- 5 sites in United States
- Volunteers
- 107 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.